Major Histocompatibility Complex peptide-binding groove (MHC groove)

The Major Histocompatibility Complex (MHC) peptide-binding groove is a specialized structural domain on MHC Class I and Class II molecules that presents antigenic peptides to T-cells (StatPearls, 2023). MHC Class I grooves, formed by alpha-1 and alpha-2 domains, typically bind 8-10 amino acid peptides, whereas MHC Class II grooves are open-ended and accommodate longer sequences (Janeway's Immunobiology). This site is fundamental for immune surveillance, allowing the detection of viral or tumor-derived antigens. Pharmacologically, the groove is a target for competitive inhibitors like glatiramer acetate, which is used to treat multiple sclerosis by displacing myelin-basic protein from MHC Class II (PubMed, PMID: 10614431). Additionally, certain drugs like abacavir bind non-covalently within the groove of specific HLA alleles (e.g., HLA-B*57:01), changing the shape of the pocket and the repertoire of presented self-peptides, which leads to drug hypersensitivity syndrome (Nature, 2012, 486:554-558). Understanding the topography of these grooves is also vital for the development of peptide-based vaccines and TCR-engineered therapies.

Other names

HLA peptide-binding cleftAntigen-binding grooveMHC binding pocketMHC cleftPeptide-binding site

Competitive displacement of antigenic peptides or allosteric alteration of the peptide-binding repertoire to modulate T-cell activation.